Skip to main content
SpringerLink
Log in

Radioimmunodetection of Cancer

  • Chapter
Targeted Molecular Imaging in Oncology

Abstract

Radiolabeled monoclonal antibodies have gained widespread acceptance as relatively receptor-specific radiopharmaceuticals for clinical applications. Over the past decade, several clinical trials have demonstrated the ability of radiolabeled antibodies to localize certain cancers with sensitivities and specificities comparable to and, in some instances, superior to conventional diagnostic modalities. The U.S. Food and Drug Administration (FDA) has approved four radiolabeled monoclonal antibody conjugates for human use: satumormab pendetide (OncoScint; Cytogen) for colorectal and ovarian cancer; arcitumomab (CEA-Scan; Immunomedics) for colorectal cancer; capromab pendetide (ProstaScint; Cytogen) for prostate carcinoma, and nofetumomab merpentan (Verluma; DuPont Radiopharrmaceuticals) for small-cell lung carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803–814.

    PubMed  CAS  Google Scholar 

  2. Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10–29.

    Article  PubMed  CAS  Google Scholar 

  3. Collier BD, Abdel-Nabi HH, Doerr RJ, et al. Immunoscintigraphy with In-111 CYT- 103 in the management of colorectal carcinoma: a comparison with CT. Radiology 1992;185:179–186.

    PubMed  CAS  Google Scholar 

  4. Serafini AN. From monoclonal antibodies to peptides and molecular recognition units. An overview. J Nucl Med 1993;34:533–536.

    CAS  Google Scholar 

  5. Landis SH, Murray T, Bodden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8–31.

    Article  PubMed  CAS  Google Scholar 

  6. Steele GB Jr. The National Cancer Data Base report on colorectal cancer. Cancer (Phila) 1994; 74:1979–1989.

    Article  Google Scholar 

  7. Galandiuk S, Wieand HS, Moertelo CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27–32.

    PubMed  CAS  Google Scholar 

  8. Doerr RJ, Kulaylat MN, Abdel-Nabi H. Imaging strategies in hepatic metastases from colorectal carcinoma. J Hepato-Biliary-Pancreatico Surg 1995;2:126–133.

    Article  Google Scholar 

  9. Nabi H, Doerr RJ, Chan H-W, et al. In-111-labeled monoclonal antibody immunoscintigra- phy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990; 175:163–171.

    PubMed  Google Scholar 

  10. Thor A, Ohuchi N, Szpak CA, et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118–3124.

    PubMed  CAS  Google Scholar 

  11. Rodwell JD, Alvarez VL, Lee C, et al. Sitespecific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632–2636.

    Article  PubMed  CAS  Google Scholar 

  12. Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study. Ann Surg 1991;214:118–124.

    Article  PubMed  CAS  Google Scholar 

  13. Markowitz A, Saleemi K, Freeman LM, et al. Role of In-111-labeled CYT- 103 immunoscintigraphy in the evaluation of patients with recurrent colorectal cancer. Clin Nucl Med 1993;18: 685–700.

    Article  PubMed  CAS  Google Scholar 

  14. Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 1991;214:118–124.

    Article  PubMed  CAS  Google Scholar 

  15. Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscitigraphy with the IMMU-4 Tc-99m Fab’ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum. Results of a pivotal phase III trial. J Clin Oncol 1996;14: 2295–2305.

    PubMed  Google Scholar 

  16. Hughes K, Pinsky CM, Petrelli NJ, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997;226:621–631.

    Article  PubMed  CAS  Google Scholar 

  17. Gulec SA, Serafini AN, Moffat FL, et al. Radioimmuno-scintigraphy of colorectal carcinoma using Tc-99m human monoclonal antibody 88BV59H21–2. Cancer Res 1995;55:5774–5776.

    Google Scholar 

  18. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974–1990. Observation from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. Cancer J Clin 1993;43:83–91.

    Article  CAS  Google Scholar 

  19. McNeil JE. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (Phila) 1990;66:1225–1233.

    Article  Google Scholar 

  20. Golimbu M, Morales P, Al-Askaris et al. CAT scanning in staging of prostatic cancer. Urology 1981;18:305–308.

    Article  PubMed  CAS  Google Scholar 

  21. Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 1989; 19:309–321.

    Article  PubMed  CAS  Google Scholar 

  22. Schellmanner PF, Wright GL Jr. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 1993;20:597–606.

    Google Scholar 

  23. Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;13:102–112.

    Google Scholar 

  24. Babaian RJ, Sayer J, Podoloff DA, et al. Radioimmunoscintigraphy of pelvic lymph nodes with In-111 MoAb CTY-356. J Urol 1994;152:1952–1955.

    PubMed  CAS  Google Scholar 

  25. Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with In-111 CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490–1495.

    PubMed  CAS  Google Scholar 

  26. Breitz HB. Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med 1993;23: 127–132.

    Article  PubMed  CAS  Google Scholar 

  27. Vansant JP. Staging lung carcinoma with Tc-99m monoclonal antibody. Clin Nucl Med 1992;17: 431–438.

    Article  PubMed  CAS  Google Scholar 

  28. Kramer EL, Noz, ME, Liebes L, et al. Radioimmuno-detection of non-small cell lung cancer using Tc-99m anticarcinoembryonic antigen IMMU-4 Fab’ fragment. Cancer (Phila) 1994;73:890–895.

    Article  CAS  Google Scholar 

  29. Goldenberg DM, Kim EE, DeLand FH, et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980;40:2984–2992.

    PubMed  CAS  Google Scholar 

  30. Lamki LM, Buzdar AU, Singletary SE, et al. In-111 B72.3 monoclonal antibody in the detection and staging of breast cancer. J Nucl Med 1991;32:1326–1332.

    PubMed  CAS  Google Scholar 

  31. Crippa F, Agresto R, Bombardieri E, et al. Preliminary results of preoperative axillary radioimmunoscintigraphy with In-111 B72.3 in breast cancer. Int J Oncol 1995;6:791–795.

    PubMed  CAS  Google Scholar 

  32. Nabi H. Antibody imaging in breast cancer. Semin Nucl Med 1997;27:30–34.

    Article  PubMed  CAS  Google Scholar 

  33. Pauletti G, Godolphin W, Pres MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;12:63–72.

    Google Scholar 

  34. Allan SM, Dean CJ, Eccles S, et al. Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2. Cell Biophys 1994;24–25:93–98.

    PubMed  Google Scholar 

  35. Waxman AD. The role of Tc-99m methoxyisobutyliso-nitride in imaging breast cancer. Semin Nucl Med 1997;27:40–54.

    Article  PubMed  CAS  Google Scholar 

  36. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 1999;24:41–48.

    Google Scholar 

  37. Rubin SC, Lewis JL Jr. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8:75–91.

    Article  PubMed  CAS  Google Scholar 

  38. Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of In-111 CTY-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 1993;48: 285–292.

    Article  PubMed  CAS  Google Scholar 

  39. Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumors with Tc-99m-labeled MoAb-170: first clinical experiences. Eur J Nucl Med 1995; 22:645–651.

    Article  PubMed  CAS  Google Scholar 

  40. Juweid M, Sharkey RM, Behn T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209–1217.

    PubMed  CAS  Google Scholar 

  41. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–1981.

    PubMed  CAS  Google Scholar 

  42. Blend MJ, Hyun H, Kozloff M, et al. Improved staging of B-cell non-Hodgkin’s lymphoma patients with Tc-99m-labeled LL2 monoclonal antibody fragment. Cancer Res 1995;55:5764–5770.

    Google Scholar 

  43. Jadadpour N. Current status of tumor markers in testicular cancer. Eur Urol 1992;21:34–36.

    Google Scholar 

  44. Fossa S, Qvist H, Stenwig A, et al. Is postchemotherapy retroperitoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569–573.

    PubMed  CAS  Google Scholar 

  45. Kim EE, DeLand FH, Nelson MO, et al. Radioimmunodetection of cancer with radiolabeled antibodies to a-fetoprotein. Cancer Res 1980;40:3008–3012.

    PubMed  CAS  Google Scholar 

  46. Kasi LP, Kim EE, Diaz M, et al. Pharmakokinetic evaluation of Tc-99m anti-AFP Fab’ in patients with germ cell tumors. J Nucl Med 1994;35:11–12 (abstract).

    Google Scholar 

Download references

Authors
  1. E. Edmund Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Nuclear Medicine and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA

    E. Edmund Kim MD  & David J. Yang PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kim, E.E. (2001). Radioimmunodetection of Cancer. In: Kim, E.E., Yang, D.J. (eds) Targeted Molecular Imaging in Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3505-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-3505-5_7

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-3507-9

  • Online ISBN: 978-1-4757-3505-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation